within Pharmacolibrary.Drugs.ATC.J;

model J04AC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.21666666666666667,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0125,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Isoniazid is a bactericidal antibiotic used primarily as a first-line agent for the prevention and treatment of tuberculosis. It is generally approved and used today, often in combination with other antitubercular medications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both sexes, after single oral dose.</p><h4>References</h4><ol><li>Emily R Erwin, Angela P Addison, Sarah Finney John, Omonike Arike Olaleye, Rosemarie C Rosell,Pharmacokinetics of isoniazid: The good, the bad, and the alternatives.,Tuberculosis (Edinburgh, Scotland),2019<a href='https://pubmed.ncbi.nlm.nih.gov/31076322/'>https://pubmed.ncbi.nlm.nih.gov/31076322/</a></li><li>Jinmeng Li, Xinjun Cai, Yueting Chen, Chenyu Wang, Zheng Jiao,Parametric population pharmacokinetics of isoniazid: a systematic review.,Expert review of clinical pharmacology,2023<a href='https://pubmed.ncbi.nlm.nih.gov/36971782/'>https://pubmed.ncbi.nlm.nih.gov/36971782/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J04AC01;
